ANNOUNCEMENTS

September 18, 2018:  TransMed7, LLC announced today the availability of Concorde, the stereotactic table variant of its SpeedBird Biopsy Device Platform.  “We are delighted to announce a letter-to-file regarding ConcordeTM, the stereotactic table variant of our FDA-cleared SpeedBirdTM soft tissue biopsy device platform,” stated Dr. James W. Vetter, TransMed7 Co-Founder and Chairman. “Like the original announcement on June 19 that the FDA had cleared our 510(k) application to market SpeedBird, this is another important step as it furthers TransMed7’s goal of developing, under the guidance of experts, critically needed, simpler to use, minimally-invasive medical technologies and distributing them into the hands of clinicians for the benefit of their patients.”

The Concorde device platform is based on TransMed7’s patented, proven Zero5TM technology, comprising a fused, single element constructed from three hypotubes and forming its multifunctional tip.  This single element tip is capable of cycling between configurations to perform the functions of an ideal biopsy procedure under various guidance modalities. Without requiring a sharp needle tip to advance through tissue or the need to first fire a sharp tip through or past the target lesion, the Concorde tip can approach, core, sever and transport multiple samples of a target lesion via a closed-circuit flush and vacuum mechanism into a detachable, proprietary, tissue preservation and transport chamber.  Concorde is a fully automated, forward coring, vacuum-assisted, single insertion, multiple-sample (SIMS) device with a simplified, cost-effective design, a single-use, fully equipped handle, which obviates the need for a console, that simplifies the entire specimen acquisition and storage procedure, which greatly facilitates ease of use for a rapid learning curve, and lowers costs for widespread adoption.  Zero5 technology enables the Concorde device to reliably and consistently obtain full-core, uniform-diameter samples with intact architecture in all types of soft tissues regardless of compliance factors.

“These devices are intended to address the many problematic issues that have been identified by highly experienced, expert colleagues in the field and are associated with current biopsy devices, including the firing of razor sharp and potentially traumatic needle tips with their required needle tip dead space, as well as tissue compliance variabilities that fundamentally limit biopsy specimen quantity, quality and consistency,” stated Dr. Edgar D. Staren, TransMed7 President and Executive Chairman of its Clinical and Scientific Advisory Board and its Business Advisory Board.  “In its letter-to-file, TransMed7 documents how Concorde’s handle is enhanced for placement on a stereotactic or 2D/3D biopsy gantry, including the provision to activate an automatic partial cycle pause and full-cycle resumption, further simplifying documentation of post-core needle position.”

According to recent publications, approximately 1.7 million breast biopsies are performed per year in the U.S.  Nearly 1.4 million of these biopsies are performed by a minimally-invasive technique and more than 300,000 of these are performed by stereotactic methodology. Equipped with the Zero5 technology, developed utilizing years of and ongoing guidance by, experts in the field, TransMed7’s SpeedBird and Concorde platforms of products are designed to ideally optimize all minimally-invasive breast biopsies.  The goal of these technologies is to enhance the ability of surgeons, radiologists, and other specialists to better serve their patients with minimally-invasive procedures through the use of simpler, more inherently precise and cost effective, next-generation, single insertion and multiple-sample biopsy devices designed to consistently and safely obtain higher quality biopsy samples from the breast.

TransMed7 has been finalizing production and market introduction strategies for the SpeedBird and Concorde rollout for both domestic and international sales and distribution.  Additionally, TransMed7 is continuing development of its portfolio of next generation soft tissue biopsy and delivery products based on innovative variations of its Zero5 working element to apply to other fields of use that likewise have significant unmet needs, including: CardinalTM, a fine-needle (21 gauge and smaller) core biopsy device for breast, thyroid, and lymph nodes, with particular application for the pediatric population; and HeronTM, a single insertion, multi-sample device with primary aim at the prostate biopsy market but also for liver and kidney biopsy. TransMed7 is also currently developing CygnetTM, a novel device designed to take advantage of Zero5’s proprietary methodology to create a continuously accessible pathway for other interventions such as aspiration and biopsy of bone marrow and delivery of treatment agents; and MartinetTM a revolutionary new minimal access device for complete target lesion removal.

Eugene H. Vetter, TransMed7’s Co-Founder and CEO, stated, “This is another bellwether moment in TransMed7’s history that marks, in addition to SpeedBird 38, Universal, and SBU 99 ultrasound-guided breast biopsy devices, the final milestone leading to the market launch of our Concorde stereotactic and 2D/3D tomosynthesis-guided breast biopsy devices in the United States which we anticipate in the coming weeks.”


July 30, 2018:  TransMed7, LLC is delighted to announce the appointment of John B. Simpson, Ph.D., M.D., as Strategic Advisor to the TransMed7 Board of Directors.

“Dr. Simpson’s remarkable history of clinical excellence, innovation, scientific achievement, and entrepreneurial expertise immediately expands TransMed7’s strategic options for rapid development and deployment of our upcoming transformational cardiovascular intervention technologies, including our Corsair and Mustang CV/PAD devices, into the market,” said Eugene H. Vetter, TransMed7’s Co-Founder and CEO. “In addition to the obvious business and clinical advantages he brings to TransMed7, we value even more his deep caring nature as a human being. His outlook and guidance will push us even harder to make all of our new technologies available as soon as possible.”

Dr. Simpson received his B.S. in Agriculture from Ohio State University and his M.S. and Ph.D. degrees in Biomedical Science from the University of Texas at Houston. He received his M.D. from the Duke University School of Medicine and completed a fellowship in interventional cardiology at Stanford University. A noted clinician, scientist, and serial entrepreneur, Dr. Simpson is widely recognized as developing the over-the-wire balloon angioplasty catheter. This invention was one of the landmark events leading to the broader application of a percutaneous approach for interventional cardiology techniques in the area of coronary and peripheral revascularization. This device was the foundation of a company called Advanced Cardiovascular Systems, Inc., in 1978 and was the first of a series of inventions by Dr. Simpson that have helped so many patients afflicted with coronary artery disease.

Dr. Simpson is a Professor of Clinical Medicine at Stanford University. He served as a Staff Cardiologist at Sequoia Hospital in Redwood City, California since 1981. He has published extensively on a wide variety of topics pertaining to interventional cardiology and has been an invited speaker throughout the world. He has been honored with the Andreas Greuntzig Award from the European Cardiology Society, the Duke University Alumni Award, the Lifetime Achievement Award from the Trans-Catheter Therapeutics Conference, and the Distinguished Alumnus for the University of Texas Graduate School of Biomedical Sciences at Houston.

Over the course of his renowned career, Dr. Simpson has founded and successfully handed off several companies including Advanced Cardiovascular Systems and Devices for Vascular Intervention, both acquired by Eli Lilly; Cardiovascular Imaging Systems, acquired by Boston Scientific; Perclose, sold to Abbott; Lumend, acquired by Cordis; and Fox Hollow, acquired by ev3 and which is now part of Medtronic. Most recently, he founded Avinger, Inc. in 2007 and served as its Chief Executive Officer through 2014 and as Executive Chairman from December, 2014 through 2017.

According to Dr. James W. Vetter, TransMed7 Co-Founder and Chairman, “Dr. Simpson is universally recognized as a true pioneer and visionary in the field of interventional cardiology including percutaneous coronary and peripheral vascular treatments. His innovations continue to be responsible for saving the lives of literally millions of patients around the world each year. While he is clearly one of the most successful serial entrepreneurs in the medical device industry, his primary motivation continues first and foremost to be, to make a positive difference in patient’s lives. All of this is consistent with TransMed7’s prime objective of improving each patient’s treatment, care, and quality of life through practical translation of new capabilities and concepts into our pipeline of transformational devices.”


July 30, 2018:  TransMed7, LLC is delighted to announce the appointment of Michael J. Cyrus as a member of its Business Advisory Board.

Mr. Cyrus joined Babcock and Brown in 2008.  He serves as Managing Partner of SteelRiver Infrastructure Partners and as the Chief Executive Officer of Trans Bay Cable.

Previously Mr. Cyrus served as CEO of the commercial business unit (CBU) at Cinergy Corp. and as its Executive VP.  As CEO of the CBU, he was responsible for wholesale electric, natural gas and coal marketing, trading and origination, international operations and unregulated energy services operations. Mr. Cyrus also oversaw energy portfolio strategy and management, which includes fuels management, environmental risk analysis, generation dispatch, load forecasting, generation asset planning, power purchases and sales decisions and portfolio analytics. Prior to joining Cinergy, Mr. Cyrus served as the Senior Vice President of trading and operations with Natural Gas Clearinghouse (NGC). His primary responsibilities included management of NGC’s power trading, transmission and real time operations. Mr. Cyrus joined Natural Gas Clearinghouse in 1993 and subsequently held officer and executive positions involving energy trading, marketing and risk management. Mr. Cyrus began his career in 1982 at Conoco Inc., in the natural gas and gas products department. He left Conoco in 1988 to work at Kottke Associates in Chicago, a member of the Chicago and New York Mercantile, Chicago Board of Trade and various world financial and commodity exchanges.

Mr. Cyrus holds a BA and MBA from the University of Arkansas. He is also a graduate of Harvard University’s Advanced Management Program, Mahler School of Advanced Management, and The Center for Creative Leadership.


July 30, 2018:  TransMed7, LLC is delighted to announce the appointment of Carin Fradin as a member of its Business Advisory Board. 

Ms. Fradin is Managing Director of Investment Banking in JMP Securities and based in the firm’s San Francisco office. Ms. Fradin is expected to bolster JMP Securities’ investment banking efforts in the medical device sector. She has an impressive background in mergers and acquisitions. She is remarkably well recognized in the healthcare arena for her unique knowledge and experience in the equity related activities in the medical device and supplies sector.

Prior to joining JMP Securities, Ms. Fradin was a Managing Director at Four Oaks Partners, a transaction advisory firm serving the life sciences industry, where she focused on the medical device space. Prior to this she was a Managing Director and Senior Advisor at investment bank Sagent Advisors. In addition, Ms. Fradin also spent 12 years in healthcare investment banking at UBS Investment Bank, most recently as a Managing Director, concentrating on the medical device and medical technology industries. Prior to that at UBS she led the U.S. execution of all cross-border medical technology transactions originated in Asia. Ms. Fradin has worked with and represented companies around the world at all stages of development, from private, pre-revenue companies to multi-billion dollar public companies.

Ms. Fradin holds a BA in mathematics and psychology from the University of Pennsylvania.


June 19, 2018: TransMed7, LLC Announces 510(k) Clearance by the U.S. FDA for its SpeedBird Soft Tissue Biopsy Device Platform.

TransMed7, LLC announced today that the United States Food and Drug Administration (FDA) has cleared its 510(k) application for the company to market the SpeedBirdTM platform of soft tissue biopsy devices.  “We are delighted to announce this 510(k) clearance by the FDA,” stated Dr. James W. Vetter, TransMed7 Co-Founder and Chairman. “This is an important landmark as it puts TransMed7 in a position to attain its goal of developing critically needed, minimally-invasive medical technologies and getting them into the hands of clinicians for the benefit of their patients as quickly as possible.”

The SpeedBird platform is based on TransMed7’s patented Zero5TM work element composed of a fused, single element constructed from 3 hypotubes and forming rotating twin cutter blades.  This element cores, severs, and provides a pathway to transport multiple tissue samples via a closed-circuit flush and vacuum mechanism into a detachable chamber.  The SpeedBird platform is characterized by fully automated or manually operated, hand-held, ultrasound-guided, single insertion, multiple sample (SIMS) devices with a simple, cost-effective design, a single-use or reusable handle, and a forward coring action, intended to facilitate ease of use for rapid learning curve and adoption.  Zero5 technology enables the SpeedBird devices to reliably and consistently obtain full-core, uniform-diameter samples with intact architecture from all of the various soft tissues.

“These devices are intended to address the many problematic issues associated with current biopsy devices including: difficulty visualizing the needle tip with real-time imaging modalities; sharp and potentially traumatic needle tips, limitations in biopsy specimen quantity and quality, and restrictions on tissue type and needle gauge,” stated Dr. Edgar D. Staren, TransMed7 President and Executive Chairman of its Clinical and Scientific Advisory Board and its Business Advisory Board.

According to recent publications, approximately 1.7 million breast biopsies are performed per year in the U.S.  Nearly 1.4 million of these biopsies are performed by a minimally-invasive technique and the vast majority of these are guided by ultrasound. Equipped with the Zero5 technology, TransMed7’s SpeedBird platform of products are ideally designed to address all minimally-invasive, ultrasound-guided, breast biopsies and with the goal of addressing the needs of surgeons, radiologists, and other clinicians who desire better minimally-invasive procedures through the use of next-generation, single insertion and multiple sample biopsy devices in a choice of sizes and which are designed to consistently and safely obtain higher quality biopsy samples from the breast.

In anticipation of 510(k) clearance, TransMed7 has been finalizing production and market introduction strategies for the SpeedBird product platform rollout for both domestic and international sales and distribution.  Additionally, TransMed7 is continuing development of its portfolio of next generation products based on innovative variations of its patented “Zero5” working element, which include: ConcordeTM, a new platform technology for stereotactic and MRI based biopsy procedures and CardinalTM, a fine-needle core biopsy device for breast, thyroid, and lymph nodes. TransMed7 is also currently developing CygnetTM, a novel device designed to establish continued access for intervention including aspiration and biopsy of bone marrow and MartinetTM a revolutionary new minimal access device for complete removal of target tissue.

Eugene H. Vetter, TransMed7’s Co-Founder and CEO, stated, “This is a bellwether moment in TransMed7’s history and represents the final milestone before the market launch of our SpeedBird 38, Universal, and SBU 99 soft tissue biopsy devices in the United States. We will be making a formal announcement upon our commercial launch which we expect to occur in the coming weeks.”


May 22, 2108:  TransMed7, LLC Announces Strategic Engagement with Wilson Sonsini Goodrich and Rosati.

TransMed7, LLC, announced a Strategic Engagement with the firm of Wilson Sonsini Goodrich and Rosati (WSGR) effective May 22, 2018.   Wilson Sonsini is the premier legal advisor to technology, life sciences, and other growth enterprises worldwide. The firm represents companies at every stage of development, from entrepreneurial start-ups to multibillion-dollar global corporations. Their services include corporate law and governance, public and private offerings of equity and debt securities, mergers and acquisitions, intellectual property litigation, antitrust counseling and litigation, joint ventures and strategic alliances, and technology licensing and other intellectual property transactions, among other areas.

Wilson Sonsini are consistently named one of “America’s Best Corporate Law Firms” by Corporate Board Member. Over the last five years Wilson Sonsini has completed more than 100 public equity and debt offerings helping clients raise more than $50 billion and has provided representation in more than 500 merger & acquisition transactions valued at over $150 billion.

According to Dr. James W. Vetter, TransMed7 Co-Founder and Chairman, “Wilson Sonsini’s established leadership position is based on their ability to provide legal services characterized by innovative advice and dynamic perspectives.  I believe that they are a perfect match for TransMed7.  We fully intend to benefit from the synergy of our unique business strategy with their deep breadth of expertise, including strategic and legal advice relating to technology development, equity transactions, mergers and acquisitions, technology licensure, and strategic planning and execution as we continue to introduce new breakthrough technologies across the board in medical interventional systems.”


May 2 – 6, 2018:  TransMed7, LLC highlighted its SpeedBird and Concorde Technologies at the 2018 Annual Meeting of the American Society of Breast Surgeons in Orlando.

ASBrS 2018 Team Picture

TransMed7, LLC highlighted its SpeedBird and Concorde technologies at the annual meeting of the American Society of Breast Surgeons (ASBrS) in Orlando, FL.

Attending on behalf of TransMed7 were Dr. James W. Vetter, TransMed7 Co-Founder and Chairman; Dr. Edgar D. Staren, TransMed7 President and Executive Chair of its Clinical and Scientific Advisory Board (CSAB) and its Business Advisory Board; Greg Carpenter, National Sales Manager for SpeedBird, LLC and Concorde, LLC; Beth Boyd, TransMed7 Clinical Coordinator; and Rob Sauchyn, TransMed7 Lead Engineer.

Also in attendance were the following TransMed7 CSAB Breast Health Team members:  Dr. Richard E. Fine, Director of Education and Research at the Margaret West Comprehensive Breast Center, Associate Professor of Surgery at the University of Tennessee College of Medicine, and Chair of TransMed7’s Breast Health Team and Executive Committee member of its CSAB; Dr. Michael Berry, Director, West Comprehensive Breast Center; Dr. Jocelyn Rapelyea, Professor of Radiology, George Washington School of Medicine; and Dr. Shawna Willey, Professor and Vice-Chair of Surgery, Georgetown University Hospital.

The meeting participants were primarily composed of surgeons who dedicate a large part or all of their practice to breast surgery. The ASBrS members were introduced to TransMed7 and its innovative portfolio of minimal access medical devices. In addition to engaging with the TransMed7 team at its booth, numerous clinicians were introduced to SpeedBird 38 and SpeedBird Universal as part of a pre-meeting workshop. In addition, a number of key opinion leaders (KOLs) attending the meeting were invited to participate in a separate, hands-on, image-guided demonstration of the devices. Comments from these clinicians and KOLs included the following: “it was very easy to visualize the rotating needle tip on ultrasound’…”the device was easy to use”…and, “the samples were large and of high quality”.

We are very pleased with the outcome of this important event and the related progress toward introducing TransMed7 and its products to this distinguished group of clinicians. These results move us ever closer toward meeting our mission to efficiently design, develop, and deliver transformational, minimal access medical devices that address patient needs from diagnosis to therapy. We look forward to initiating our commercial product launch shortly after receiving 510k clearance, expected before the end of the 2nd quarter, 2018.


May 1, 2018:  TransMed7, LLC announced the appointment of National Sales Manager Greg Carpenter for Concorde MD, LLC.

Mr. Greg Carpenter joins TransMed7 as the National Sales Manager of Concorde MD, LLC.

Mr. Carpenter has demonstrated himself to be a proven business sales strategy and implementation leader with progressive experience enhancing sales, growing P&L, and expanding market share in the medical device sector.  While most recently with Siemens Healthcare Division as its Senior Director of Partner Management, Mr. Carpenter spent the previous 11 years in progressively increased roles with Hologic rising from Regional Sales Representative to Regional Sales Director and ultimately to its corporate Business Director.  At Hologic he successfully introduced disruptive medical technology benefitting patients with diseases of the breast including most recently, 3D breast imaging.   In doing so he helped take this very new concept forward and ultimately made it standard of care.  He has particular expertise in organic sales growth, leveraging partnerships, evaluating market dynamics, and creating strong sales strategies.


April 11 – 15, 2018:  TransMed7, LLC highlighted its SpeedBird, Concorde, and Cardinal technologies at the Annual Meeting of the Society of Breast Imaging in Las Vegas.

Attending the annual meeting of the Society of Breast Imaging (SBI) in Las Vegas on behalf of TransMed7 were Dr. James W. Vetter, TransMed7 Co-Founder and Chairman; Dr. Edgar D. Staren, TransMed7 President and Executive Chair of its Clinical and Scientific Advisory Board (CSAB) and its Business Advisory Board; and Beth Boyd, RN, TransMed7 Clinical Coordinator.  Also attending were Dr. Richard E. Fine, Director of Education and Research at the Margaret West Comprehensive Breast Center, Associate Professor Surgery at the University of Tennessee College of Medicine, and Chair of TransMed7’s Breast Health Team and Executive Committee member of its CSAB; and Dr. Jocelyn Rapelyea, Professor of Radiology, George Washington School of Medicine, and TransMed7 CSAB Breast Health Team member.  Mr. Greg Carpenter was also in attendance at the meeting:  Mr. Carpenter will be officially joining TransMed7 as National Sales Manager for Concorde MD, LLC, a subsidiary of TransMed7.

The meeting participants were primarily composed of radiologists who are dedicated to the practice of breast imaging and image-guided intervention.  These clinicians were introduced to TransMed7 and its innovative portfolio of minimal access medical devices (currently under development).  In additon to engaging with the TransMed7 team at its booth, a number of key opinion leaders (KOLs) attending the meeting were invited to participate in a separate, hands-on, image-guided laboratory demonstration of the devices. Comments from these KOLs included:  “It was very easy to visualize the rotating needle tip on ultrasound: …The device was easy to use”…and, “The samples were large and of high quality”.

We are pleased with the results of this important event and the related progress in introducing TransMed7 and its upcoming products to this distinguished group of clinicians.  These results move us further down the path to meet our goals of efficiently designing, developing, and delivering transformational, minimal access medical devices to meet the needs of patients from diagnosis to therapy.

SBI boot picture


March 1, 2018:  TransMed7 announced the appointment of Breast Health expert Jocelyn Rapelyea, MD to the company’s Clinical and Scientific Advisory Board (CSAB).

TransMed7, LLC is delighted to formally announce that Jocelyn Rapelyea, MD, has joined it’s Clinical and Scientific Advisory Board (CSAB). Dr. Rapelyea is a Professor of Diagnostic Radiology at The George Washington University School of Medicine & Health Sciences and also serves as Associate Director of Breast Imaging and as Program Director of the Radiology Residency Program.
Dr. Rapelyea received her medical degree from the University of Medicine and Dentistry of New Jersey. She then completed her radiology residency and fellowship in breast imaging and intervention at The George Washington University Hospital.

Dr. Rapelyea is a member of several professional societies including the American College of Radiology, American Medical Association, the Society of Breast Imaging, and the American Roentgen Ray Society. Recognized as an expert in the field of breast imaging, Dr. Rapelyea is listed as a Castle Connolly Top Doctor and Top Radiologist. She is widely published in several scientific journals including the Journal of Women’s Imaging, Radiology, The Breast Journal, and Clinical Radiology. Dr. Rapelyea is regularly asked to give invited national and international presentations and has even presented to Congress on Imaging of Breast Implant Patients.

Dr. Edgar Staren, TransMed7 President and Executive Chairman of its CSAB stated, “Dr. Rapelyea’s experience and perspective as a highly respected Radiologist and expert in this field greatly enhances our Breast Health Team’s depth and focus, which is essential to us as we finalize our goals of delivering our next generation breast biopsy platform devices – SpeedBird™ and Concorde™ – for increased patient safety and comfort and superior tissue sample quality.”


February 23, 2018:  TransMed7 held a Key Opinion Leader (KOL) Symposium at the company’s new corporate offices in Phoenix, AZ.

KOL Symposium final

Panel A:  Dr. Richard Fine (Chair, TransMed7 Breast Health Team, Exec. Team of TransMed7 CSAB) demonstrating an ultrasound guided biopsy using a SpeedBird device to (from left to right) Jocelyn Rapelyea, M.D. (Professor of Radiology, George Washington School of Medicine), Thomas Eisenhauer, M.D. (Chairman, Comprehensive Cancer Center UNC at Pardee), Shawna Willey, M.D. (Professor and Vice-Chair of Surgery, Georgetown University Hospital).

Panel B:  Dr. James Vetter (Chairman, TransMed7 Board and CSAB) demonstrating the SpeedBird and Concorde devices to (from left to right) Michael Berry, M.D. (Director, West Comprehensive Breast Center), Lorraine Tafra, M.D. (Director, Breast Center of Decesaris Cancer Institute), Linda Han, M.D. (Professor and Director of Breast Surgical Oncology, Indiana Univ. Simon Cancer Center), Jocelyn Rapelyea, M.D., and Thomas Eisenhauer, M.D.

Others not pictured include: Michele Carpenter, M.D. (Breast Program Director and Chief of Staff, St. Joseph Hospital Orange CA), Michael Demeure, M.D. (Chair, TransMed7 GI/Endocrine Health Team and Program Director for Precision Medicine at the Hoag Family Cancer Institute), Sommer Gunia, D.O. (Comprehensive Breast Center of AZ), Scott Karlan, M.D. (Director of Education, Brandman Breast Center of Cedars-Sinai), and Judy Song, M.D. (Chief of Breast Imaging, Georgetown University Hospital).


January 22, 2108:  David Harding to Join TransMed7, LLC Business Advisory Board

Portola Valley, CA, January 22, 2018;  TransMed7, LLC, today announced the addition of David Harding to its Business Advisory Board.  The TransMed7 Business Advisory Board is composed of accomplished business experts offering innovative advice and dynamic perspectives that will contribute to the accomplishment of TransMed7’s tactical goals and strategic objectives.  These experts represent a carefully selected group of proven innovators, each of whom has already established his or her reputation based on high ethical standards, demonstrated leadership, and a willingness to embrace and support a mission for the good of others.  The Members of the Business Advisory Board provide TransMed7’s Senior Management Team with expanded business perspectives in a constantly changing environment, and each Member brings a focus and particular emphasis on one or more of a number of critical business sectors.

Mr. Harding is currently the Senior Vice-President (SVP) of Corporate Strategy and Business Development at Exact Sciences, a diagnostics company focused on colorectal cancer screening.  Prior to this role, he was the Chief Commercial Officer at both T2Biosystems, a company focused on innovative approaches to infectious disease testing, and OvaScience, a fertility-oriented biotech.  Previously, Mr. Harding held a variety of business unit leadership positions at Hologic, a global healthcare and diagnostics company, over the course of 10 years, culminating in being named the SVP and General Manager of the $1.2 Billion Women’s Health business unit.  Prior to Hologic, he was a partner and associate at McKinsey & Company, where he focused on corporate and commercial strategy.  Mr. Harding earned his MBA from the University of Pennsylvania’s Wharton School of Business and his Bachelor of Science in Aerospace Engineering from the University of Southern California.

“We are honored to have David Harding join the internationally recognized leaders of our Business Advisory Board,” commented Eugene H. Vetter, TransMed7 CEO and Chairman of the Business Advisory Board.  “In addition to his unique business perspectives, David brings senior management and operational experience to our organization, which will be integral to TransMed7’s commercial launch of our critically needed, minimally-invasive medical technologies to get them into the hands of clinicians for the benefit of their patients around the world as rapidly as possible.”

“Each of the members of our BAB brings years of successful experience across many of the important industries related to and supportive of TransMed7’s mission,” said Dr. Edgar D. Staren, President of TransMed7 and Executive Chairman of the Business Advisory Board.   “We are grateful that David Harding has kindly expressed his willingness to serve as a member of this illustrious group, and we look forward to benefitting from his and their judgment and counsel.”

In anticipation of 510(k) clearance expected in the second quarter of 2018, TransMed7 is finalizing production and market introduction strategies for its SpeedBird™ soft tissue biopsy product platform and its Concorde™ platform technology for stereotactic and MRI based biopsy procedures, with rollout for both domestic and international sales and distribution.  The TransMed7 Business Advisory Board will provide crucial guidance as TransMed7 continues development of its portfolio of next generation products based on innovative variations of its patented “Zero5” working element.  These products include, in addition to the above: Cardinal™, a fine-needle core biopsy device for breast, thyroid, and lymph nodes; and Cygnet™, a novel device designed to establish continued access for intervention including aspiration and biopsy of bone marrow.  TransMed7 is also currently developing Martinet™, a revolutionary new minimal access device for complete removal of target tissue.


December 11, 2017:  TransMed7, LLC Announces Inaugural Members of its Business Advisory Board

Portola Valley, CA, December 11, 2017; TransMed7, LLC today announced the creation of, and inaugural appointments to, its Business Advisory Board.  The TransMed7 Business Advisory Board is composed of accomplished business experts offering innovative advice and dynamic perspectives that will contribute to the accomplishment of TransMed7’s tactical goals and strategic objectives.  These experts represent a carefully selected group of proven innovators, each of whom has already established his or her reputation based on high ethical standards, demonstrated leadership, and a willingness to embrace and support a mission for the good of others.  The Members of the Business Advisory Board provide TransMed7’s Senior Management Team with expanded business perspectives in a constantly changing environment, and each Member brings a focus and particular emphasis on one or more of a number of business sectors, including but not limited to the following areas:

  • Strategic Planning, including Tactical Execution;
  • Commercial Launch of new Platform Technologies;
  • S. and O.U.S.-based Distributors and Sales Networks;
  • Corporate Relations Analysis and Development;
  • International Business Management and Strategic Market Development;
  • Financial Management, Fundraising and Investment Performance Options;
  • Corporate Compliance and Tax Planning Advice; and
  • Public Relations, Networking, Communications and Advocacy.

“We are honored to have these internationally recognized leaders as the founding members of our Business Advisory Board”, commented Eugene H. Vetter, TransMed7 CEO and Chairman of the Business Advisory Board.  “In addition to their individual business perspectives, they bring additional experience as founders, inventors, and entrepreneurs to our organization and will be integral to TransMed7’s commercial launch of our critically needed, minimally-invasive medical technologies to get them into the hands of clinicians for the benefit of their patients around the world as rapidly as possible.”

The inaugural members include:

Tony Astorga – Mr. Astorga actively serves on several both public and private boards including his current position as Chairman of the Board at the Arizona Hispanic Chamber of Commerce Foundation. He also serves as a financial consultant to AZTOR Health and Wealth Management Advisors.  Mr. Astorga formerly served as Senior Vice President, CFO, and Chief Business Development Officer for Blue Cross Blue Shield (BCBS) of Arizona as well as the President of BCBS of Mexico. A graduate of Arizona State University with a Bachelor in Accounting, Mr. Astorga is a CPA and former founding partner of Astorga and Maurseth, Certified Public Accountants.

Mark Bradley – Most recently Mr. Bradley served as CEO and Board Member of Conversica; one of the fastest growing artificial intelligence companies in the world. He currently serves on several boards in the technology and education sectors including the Southern Methodist University (SMU) Lyle School of Engineering. Prior to this, Mr. Bradley was a Co-Founder, President, and Senior Vice President of Global Product Shopping/International/Operations of NexTag, known for its popular consumer website providing price comparison shopping information and which exited in 2007 for $1.3B after opening successful operations in 9 countries. Mr. Bradley is a graduate of Southern Methodist University with a Bachelor in Finance.

Carlos Collazo – Starting from his facilitating creation of the current Standard International Trade Commodity Classification System, Mr. Collazo has leveraged his expertise to found and/or lead several successful technology companies. These include Mariner Systems Incorporated (MARSYS) where he was the Founder, CEO, and Chairman until it was sold in 2013. The MARSYS Group of companies consisted of associated companies in the information technology and services industry and delivered technology services to Fortune 500 companies in over 20 countries for more than 30 years.  The derivative works from the core technologies developed under Mr. Collazo’s leadership are still in productive use in the market via licenses and/or acquisitions and include applications to cyber security, systems optimization, digital media, data analytics, education, trade systems and others. Mr. Collazo has served on the boards of several educational institutions and leadership councils including Notre Dame University and the Cyber Intelligence Initiative. He is a graduate of Oklahoma State University.

Thomas Cowan – Mr. Cowan is Director of The Center for Technology Management at Columbia University and most recently served as CEO at modomodo, a SaaS mobile application development platform company.  Mr. Cowan is recognized as a technology CEO and entrepreneur creating value through execution with particular expertise in enterprise software, Big Data analytics, and SaaS delivery.  He spent more than two decades at IBM starting in Finance and moving to CFO and GM roles. He subsequently served as Chairman and CEO of OutlookSoft, a leading developer of business performance software, and positioned the company for its acquisition by SAP.  At Vcommerce, a pioneer developer of e-commerce software, Mr. Cowan served as Chairman/CEO/COO/CFO where he led a successful restructuring and which established the basis for later acquisition by Google.  Mr. Cowan has served on numerous public and private boards including SMTC Corporation, Wake Forest University, and Tivoli Systems. He is the author of From Idea to Business, Business Basics, and Leadership Basics. He received his Bachelor in Economics from Wake Forest University and an MBA from the University of South Carolina.

“Each of the inaugural members of our Business Advisory Board bring years of successful  experience across many of the  important industries related to and supportive of TransMed7’s mission (“to efficiently design, develop, and deliver transformational, minimal access medical devices which address patient needs from diagnosis to therapy”),” said Dr. Edgar D. Staren, President of TransMed7 and Executive Chairman of the Business Advisory Board.   “We are grateful for their willingness to serve as Business Advisory Board members and look forward to benefitting from their judgment and counsel.”

In anticipation of 510(k) clearance expected in the first quarter, 2018, TransMed7 is finalizing production and market introduction strategies for its SpeedBird™ soft tissue biopsy product platform and its Concorde™ platform technology for stereotactic and MRI based biopsy procedures, with rollout for both domestic and international sales and distribution.  In addition, the Business Advisory Board will provide crucial guidance as TransMed7 continues development of its portfolio of next generation products based on innovative variations of its patented “Zero5” working element, which include: Cardinal™, a fine-needle core biopsy device designed for breast, thyroid, and lymph nodes; and Cygnet™, a novel device designed to establish continued access for intervention including aspiration and biopsy of bone marrow.  TransMed7 is also currently developing Martinet™, a revolutionary new minimal access device designed for complete removal of target tissue.


October 17, 2017:  TransMed7, LLC Announces 510(k) Submission to the U.S. FDA for its SpeedBird Soft Tissue Biopsy Device Platform

Portola Valley, CA, October 17, 2017; TransMed7, LLC today announced that it has submitted a premarket notification for its innovative SpeedBird soft tissue biopsy device platform with the US Food and Drug Administration (FDA), under Section 510(k) of the Food, Drug and Cosmetic Act. “We are pleased to announce this 510K submission to the FDA, which represents the final countdown to the rapid market launch of our SpeedBird 38, Universal, and SBU 99 soft tissue biopsy devices in the United States, expected in the first quarter of 2018,” said Eugene H. Vetter, TransMed7’s Co-Founder and CEO.

The SpeedBird  product platform of hand-held soft tissue biopsy devices has been designed to fulfill the needs of surgeons, radiologists, and other clinicians who desire better minimally invasive procedures through the use of next-generation, cost-effective, single insertion and multiple sample (SIMS) biopsy devices in a choice of sizes and which is designed to consistently and safely obtain higher quality biopsy samples from the breast, liver, kidney, prostate, spleen, lung, lymph nodes, and other soft tissue abnormalities identified  by physical exam, X-rays, or ultrasound.

In anticipation of 510(k) clearance, TransMed7 is finalizing production and market introduction strategies for the SpeedBird product platform rollout for both domestic and international sales and distribution.  Additionally, TransMed7 is continuing development of its portfolio of next generation products based on innovative variations of its patented “Zero5” working element, which include: Concorde™, a new platform technology for stereotactic and MRI based biopsy procedures; Cardinal, a fine-needle core biopsy device for breast, thyroid, and lymph nodes; and Cygnet, a novel device designed to establish continued access for intervention including aspiration and biopsy of bone marrow.  TransMed7 is also currently developing Martinet™, a revolutionary new minimal access device for complete removal of target tissue.

According to Dr. James W. Vetter, TransMed7 Co-Founder and Chairman, “We are delighted to achieve this important milestone as it puts TransMed7 closer to its goal of developing critically needed, minimally-invasive medical technologies and getting them into the hands of clinicians for the benefit of their patients as quickly as possible.”

Caution: The SpeedBird 38, Universal, and SBU 99 soft tissue biopsy devices are investigational devices, which pending FDA clearance, are not as yet available for sale.


October 10, 2017:  TransMed7, LLC Announces Endocrine and GI Health Chair Appointment

TransMed7, LLC today announced the appointment of Michael J. Demeure, MD, MBA, as Chair of its Endocrine and Gastrointestinal (GI) Health Team and Member of its Executive Team of TransMed7’s Clinical and Scientific Advisory Board (CSAB). “We are honored to have Dr. Demeure as Chair of our Endocrine and GI Health Team.  Recognized as one of the top surgeons in the United States, Dr. Demeure is keenly interested in new transformational medical technologies that will help all physicians realize more precise diagnostic and therapeutic interventions,” said Eugene H. Vetter, TransMed7’s Co-Founder and CEO.  “In his role, he will be responsible for leading TransMed7’s Endocrine and GI Health Team in achieving our goal of developing and rapidly fielding new minimally invasive medical technologies integrated with advanced imaging modalities, beginning with Cardinal™ – our new platform technology for fine-needle core biopsy procedures”.

Dr. Demeure is the Program Director for Precision Medicine at the Hoag Family Cancer Institute and a fellowship-trained endocrine surgeon with the Newport Irvine Surgical Specialists group.  He is also an Adjunct Professor at the Translational Genomics Research Institute (TGen), and previously a Clinical Professor of Surgery at the University of Arizona, College of Medicine in Phoenix, AZ.   Dr. Demeure is a 1983 graduate of Hahnemann Medical College and completed his surgical residency at the University of Arizona.   He subsequently completed a fellowship in endocrine surgery in Perth, Australia and at the University of California, San Francisco. He previously held faculty positions at the Medical College of Wisconsin, as Professor and Chief of General Surgery at the University of Arizona, and most recently as Scientific Director, Center for Pancreatic and Endocrine Surgery, Scottsdale Healthcare and Professor and Director of the Rare Tumors Program in the Division of Integrated Cancer Genomics at TGen. In 2007, Dr. Demeure completed his MBA at the University of Arizona.

Dr. Demeure is an internationally recognized expert in cancer surgery and research with particular expertise in endocrine, pancreatic and gastrointestinal cancers. In addition to a very active clinical practice, Dr. Demeure has led a highly productive research lab for over 20 years focused on using genomic technologies to develop novel biomarkers, new therapeutic targets, and related therapies in the management of endocrine and gastrointestinal cancers; this has led to his being the Co- or Principle Investigator on several of the landmark trials in these same areas. Dr. Demeure is the author or co-author of over 100 scholarly works and he has given over 150 invited lectures and presentations. Dr. Demeure is a past-President of the American Association of Endocrine Surgeons, is regularly recognized as one of “America’s Top Surgeons” and has been named as one of the “Best Doctors in America” every year since 2001. Prior to his move to the Hoag Family Cancer Institute at Hoag Hospital, he helped TGen with the launch and direction of Ashion Analytics, a commercial clinical sequencing lab serving as its Chief Medical Officer, Executive Vice-President and General Manager.

“I am delighted to be joining TransMed7’s talented and enthusiastic team of clinicians, scientists, and engineers in developing and implementing new breakthrough diagnostic and therapeutic technologies for the benefit of patients everywhere”, said Dr. Demeure.

According to Dr. James W. Vetter, TransMed7 Co-Founder and Chairman, “Dr. Demeure brings valuable leadership experience in the rapidly expanding field of precision medicine and distinctive expertise in endocrine and gastrointestinal diseases. We look forward to his guidance as we build on our strengths in the field of image-guided, minimal access intervention to rapidly make a difference in the lives of patients in need”.


September 25, 2017:  TransMed7, LLC Announces Breast Health Chair Appointment

TransMed7, LLC, announced the appointment of Richard E. Fine, MD, as Chair, Breast Health Team and Member, Executive Team of TransMed7’s Clinical and Scientific Advisory Board (CSAB). “We are honored to have Dr. Fine as Chair of the distinguished leaders in our Breast Health Team.  He brings to our organization more than 20 years’ experience as a nationally recognized pioneer in breast care”, said Eugene H. Vetter, TransMed7’s Co-Founder and CEO.  “In his new role, he will be responsible for helping TransMed7 and particularly, our Breast Health Team, achieve their goal of developing critically needed, minimally-invasive medical technologies and getting them into the hands of clinicians for the benefit of their patients as rapidly as possible, with particular emphasis on launching Concorde™, our new platform technology for stereotactic and MRI based biopsy procedures, and Martinet™, our novel minimal access device for complete removal of target tissue”.

Since 2012, Dr. Fine has been the Director of Education and Research at the Margaret West Comprehensive Breast Center. In addition, he is the Program Director, West Cancer Center Breast Surgical Oncology Fellowship and Associate Professor in the Department of Surgery, Division of Surgical Oncology at the University of Tennessee Health Science Center, College of Medicine.  Dr. Fine holds or has held several positions of national prominence in breast care including Presidency of the American Society of Breast Surgeons from 2003-2004, Chairman of the Board of the American Society of Breast Surgeons, Chairman of the Board of the American Society of Breast Surgeons Foundation, Co-Chair of the American College of Surgeons National Ultrasound Faculty Breast Imaging Module, and Board Member of the National Accreditation Program for Breast Centers (NAPBC) and the National Consortium of Breast Centers (NCBC).

Dr. Fine received his undergraduate degree in Chemistry at Emory University, Atlanta, GA, in 1979 and his MD at the Medical College of Georgia, Augusta, GA, in 1983. He subsequently performed his Surgery Residency at Rush-Presbyterian-St. Luke’s Medical Center from 1983-1988 in association with noted breast care pioneers, Dr. Steven G. Economou and Dr. Kambiz Dowlatshahi.  Dr. Fine has received numerous awards including the American Medical Association Physicians Recognition Award, 1991-2010, and most recently recognition as a “Top Doctor” in Memphis Magazine, 2014-2017.

A highly sought-after educator and acknowledged thought leader in the use of ultrasound and image-guided technology, Dr. Fine has published numerous articles and written several book chapters related to stereotactic and ultrasound core needle breast biopsy. He continues as a member of several breast research endeavors including the Scientific Advisory Board for the IceCure™ Medical IceSense3 Cryotherapy for Breast Cancer Trial and multiple clinical studies on Image-guided Breast Biopsy Technology. Dr. Fine has served on numerous advisory panels for both established and start-up organizations in developing and bringing to market new technology in the breast space. “I am delighted to be part of the talented team of committed clinicians, scientists, and engineers at TransMed7, all dedicated to provide difference making minimal access medical technology for patients with breast disease”, says Dr. Fine.

According to Dr. James W. Vetter, TransMed7 Co-Founder and Chairman, “Dr. Fine is a true innovator in the diagnosis and treatment of breast diseases.  In addition to being one of the first surgeons in the country to perform stereotactic-guided needle core biopsy, he has since remained on the forefront of education and technology development in the field of image-guided, minimal access breast intervention”.


September 11, 2017:  TransMed7, LLC Announces Strategic Partnership with Peridot Corporation

Portola Valley, CA, September 11, 2017; TransMed7, LLC, today announced a Strategic Partnership between TransMed7, LLC and Peridot Corporation effective August 21, 2017.  Both are privately held companies: TransMed7 designs and develops transformational medical device technologies for diverse fields of healthcare while Peridot offers complete end-to-end precision manufacturing and clean room assembly services.

“This new Strategic Partnership with Peridot enables TransMed7 to launch new products such as our Concorde™ and Martinet™ technologies directly into the market immediately following FDA clearance.  Peridot was our contract manufacturer for our SpeedBird™ platform needle sets, and we are excited to be expanding our relationship with Peridot for timed product commercial release in significant quantities for strategic market penetration, ” said Eugene H. Vetter, TransMed7’s Co-Founder and CEO.  According to Dr. Edgar D. Staren, TransMed7’s President and President of Martinet Medical, LLC, a TransMed7 subsidiary Project Company, “TransMed7’s technology pipeline covers multiple, diverse medical fields with broad applications including breast, abdominal, thoracic, head and neck, urologic, endoscopic, robotic, laparoscopic, and therapeutic endovascular. This partnership with Peridot positions TransMed7 well to provide the novel, revolutionary tools for the great many fields where targeted, minimally invasive approaches are determined to be the preferred option”.

“The Peridot Team is truly gratified and very excited to have been chosen as the Strategic Partner by TransMed7 in this endeavor. Peridot’s deeply diverse technical capabilities in the field of minimally invasive devices coupled with our demonstrated agility will certainly enable TransMed7 to meet and exceed their clinical goals. This is an incredible opportunity for Peridot to be at the forefront of developing technologies that are sure to lead to better patient outcomes”, said Patrick Pickerell, Peridot Co-Founder and President.

According to Dr. James W. Vetter, TransMed7 Co-Founder and Chairman, “Peridot’s established leadership position highlights their ability to apply the widest and most enabling range of manufacturing capabilities far upstream into initial iteration phases, to which they have coupled unmatched quality and tracking systems that mesh perfectly with TransMed7’s own industry-leading standards of quality during creation, verification and validation phases.  As a result, together we are able to streamline the entire process from initial design, to clearance, and to market release with instruments ready for widespread distribution and confident clinical use. TransMed7 and Peridot share a rare, profoundly important synergism, which results in a collective capability to satisfy our mutual passion to vastly accelerate development and delivery of the most cost-effective, highest quality, safest and by far most advanced technologies possible–to patients around the globe”.

About Peridot Corporation

Peridot Corporation offers complete end-to-end precision manufacturing and clean room assembly services to a wide range of industries. With over twenty years’ experience with device fabrication and precision miniature and micro-miniature component assembly, Peridot can design, prototype, test and deliver products with the utmost precision and versatility.  At Peridot we actively and avidly engage with our customers in all phases of pre-production planning and production, as well as material and cost analysis. Our thorough working knowledge of production processes, materials and finishes becomes an integral part of a customer’s planning process resulting in our delivery of manufactured custom components that are as precisely functional as they are perfectly beautiful. Moreover, from the smallest micro-miniature components to the biggest new ideas, we bring unmatched quality and precision to every medical product we manufacture. For more information about Peridot Corporation, please visit our website at www.peridotcorp.com.


July 24, 2017:  TransMed7, LLC Announces Appointment of Jack Cumming as Director

Portola Valley, CA, July 24, 2017:  TransMed7, LLC today announced the appointment of industry veteran Jack Cumming as a member of its Board of Directors.  Mr. Cumming currently serves as CEO & Managing Director of Cumming & Associates, LLC, a strategic advisory firm formed in 2014 to exclusively serve the healthcare industry.

Prior to launching Cumming & Associates, Mr. Cumming spent fourteen years at Hologic, Inc., a publicly listed NASDAQ company.  He joined Hologic in August 2000 as Senior Vice President and President of Lorad, a Hologic company.  Mr. Cumming was promoted to President & CEO of Hologic in 2001 and later assumed the role as Chairman.  He stepped down as Chairman in September of 2011 to serve as Global Strategic Advisor with a focus on expanding Hologic’s international presence. However, in July of 2013 the Board of Directors asked Mr. Cumming to reassume the role of President & CEO with the express direction of restructuring the company.  Mr. Cumming formally retired from Hologic in December of 2013.

Under Mr. Cumming’s leadership of Hologic, beginning in 2001, Hologic’s market capitalization increased from $78 million to over $10 billion, while revenues grew from approximately $100 million to over $2.5 billon.  Moreover, during this time period the company acquired over a dozen companies whose products harmonized their women’s health care portfolio.  Hologic achieved an unprecedented market share leadership position in nine categories spanning Breast Health, Diagnostics, and Surgical.  Mr. Cumming directly attributes this achievement to the entire Hologic team whose passionate, dedicated, and unwavering belief in making a difference in the lives of women differentiated them from their competitors.  In 2007, Frost & Sullivan named Mr. Cumming CEO of the Year.  In 2011, Mr. Cumming was named recipient of the 2011 National Consortium of Breast Centers Inspiration Award winner.

“Jack’s proven leadership and extreme business acumen immediately expand TransMed7’s strategic options for rapid deployment of our transformational technologies into the market,” said Eugene H. Vetter, TransMed7’s Co-Founder and CEO.  TransMed7’s President, Dr. Edgar D. Staren stated that, “Jack’s unique depth of industry knowledge and proven success will help us advance our business as we bring to market medical technology which addresses patient needs from diagnosis to therapy.”

Prior to joining Hologic, Mr. Cumming served as President and Managing Director of HealthCare Markets Group (HCMG), a strategic advisory and investment-banking firm he founded in 1984.  In his capacity as Managing Director of HCMG, the firm completed over $2.0 billion in transactions.  Mr. Cumming is Trustee of Counsel at Bentley University and is also a member of the Luther Rice Society of The George Washington University.   He joined the Board of T2 BioSystems in 2014 and serves on its corporate governance and nominating committees.   Mr. Cumming also serves as a member of the Finance Committee for the Radiological Society of America.   Mr. Cumming and his wife Pamela are active in the Cumming Family Foundation, which was established to fund projects primarily focused on health issues for women and children globally.

Mr. Cumming stated, “I am delighted to join the TransMed7 Board because I view their products as transformational, having the breadth of scope and runway of potential applications to multiple diseases, including breast tissue biopsy and excision, bone marrow biopsy and aspiration, cardiovascular intervention, endoscopy, laparoscopy, and others. TransMed7’s multiple, worldwide, and interlocking patent coverage of all aspects of its next generation minimal access medical technology position it to provide highly reliable, multi-use devices that are cost-effective and built to ensure ease of use by clinicians and enhanced access for patients.”

According to Dr. James W. Vetter, TransMed7’s Co-Founder and Chairman, “Jack’s exceptional leadership and management experience will continue to be instrumental in formulating our strategic direction as we advance TransMed7’s prime objective of improving each patient’s treatment, care, and quality of life through delivery of our innovative pipeline of transformational medical devices”.


June 15, 2017:  TransMed7, LLC Announces Appointment of Dr. Edgar Staren as President

Portola Valley, CA, June 15, 2017:  TransMed7, LLC today announced the appointment of Edgar D. Staren, MD, PhD, MBA as TransMed7’s President as well as President of Martinet Medical, LLC, a new subsidiary Project Company among its portfolio, effective July 1, 2017.  “Dr. Staren brings more than 20 years’ experience as a successful healthcare executive leading clinical programs, facilities, and biotechnology startups as well as operations management in both for-profit and not-for-profit arenas”, said Eugene H. Vetter, TransMed7’s Co-Founder and CEO.  “In his new role, Dr. Staren will be responsible for taking our overall business strategy to the next level, as well as managing operations, quality, and financial performance for both TransMed7 and each of our Project Companies.  We are fortunate to be able to add Dr. Staren’s leadership and experience to our mix, and look forward to the new impetus he brings to the growth of our business.”

Dr. Staren will be leaving his current position as Professor of Surgery, VP and Executive Director for Cancer Services at Wake Forest University Baptist Health, and Deputy Director for Clinical Affairs of its Comprehensive Cancer Center where he fostered tremendous growth in cancer services, enhanced clinical efficiencies, and drove substantial increase in operating income.  Immediately prior to this he served as CEO of Ashion PMed Management, LLC and President of its subsidiary, Ashion Advanced Individual Medicine, LLC, both outgrowths of the Translational Genomic Research Institute (TGen) and now an affiliate of the City of Hope Comprehensive Cancer Center.

A graduate of Loyola University School of Medicine, Dr. Staren received his surgical training at Rush University Medical Center and Cook County Hospitals; he remained at Rush as a faculty member where he held positions as Professor and Associate Dean. He subsequently was recruited as Professor and Chairman of Surgery at the Medical College of Ohio and Medical Director of the MCO Cancer Institute.  He then served as Senior Vice President and Chief Medical Officer, Western Regional Medical Center CEO, and CEO of Cancer Treatment Centers of America (CTCA) Medicine and Science before joining Ashion.

Dr. Staren has been regularly listed in “Best Doctor’s in America” and “America’s Top Doctors for Cancer”.  He is a member of numerous academic organizations including the American Surgical Association, the American Society of Clinical Oncology, and the Society of Surgical Oncology, and he is a Past President of the American Society of Breast Surgeons.  He has published nearly 300 scientific works including more than 150 manuscripts, 80+ abstracts, 45 book chapters, and 12 books.  He has given more than 200 visiting professorships or invited lectures. “I feel most fortunate to be joining a remarkably talented team dedicated to bringing their combined expertise to bear in order to make a difference in the lives of patients in need”, says Dr. Staren.

According to Dr. James W. Vetter, TransMed7 Co-Founder and Chairman, “Dr. Staren has been a pioneer and strong advocate for the enhanced use of minimally invasive, image-guided procedures throughout his career.  Along with his proven operational excellence, Dr. Staren brings his extensive experience with the latest diagnostic and treatment advances to further advance TransMed7’s prime objective of improving each patient’s treatment, care and quality of life through practical translation of new capabilities and concepts into our pipeline of transformational devices”.